Greater Efficacy With Secukinumab Treatment Is Associated With Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data
Background: Psoriasis negatively affects patients’ quality of life. Secukinumab is a human interleukin-17A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis. Objectives: The current analysis evaluated the benefits of secukinumab by assessing relationships between disease severity and patient-reported symptoms. Methods: Correlations between psoriasis-related itching, pain, and scaling and disease severity scores (Psoriasis Area and Severity Index [PASI] and Investigator’s Global Assessment [IGA]) were evaluated at baseline, Week 12, and change from baseline to Week 12 using secukinumab clinical data from ERASURE and FIXTURE. Symptom responder status and PASI/IGA change were evaluated using logistic modeling. Results: Correlation coefficients ranged 0.11-0.49 for PASI and 0.19-0.52 for IGA. Greater PASI response was related to greater symptom response/complete relief. Conclusions: Results further demonstrate the relationship between traditional clinical measures of disease severity and patient-reported, psoriasisrelated itching, pain, and scaling — hence the need to consider both outcomes together to evaluate treatment effects in this disease fully.
Gottlieb, A. B., Strober, B., Kaurmann, R., Pariser, D., Narbutas, R., Nyirady, J., Xhao, Y., Herrera, V., McLeod, L., Odom, D., & Elewski, B. (2017). Greater Efficacy With Secukinumab Treatment Is Associated With Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data. Journal of Psoriasis and Psoriatic Arthritis, 2 (2), 73-80. https://doi.org/10.1177/247553031700200206